Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Dec 09, 2022 1:52pm
157 Views
Post# 35162233

RE:RE:Before we go too far...

RE:RE:Before we go too far...Yes, craighenry, on July 10, 2020, a Friday, shortly after the Chiesi press release, DrDR called me and said, quote, "Maybe you should take a break from Stockhouse."

I was pleased with the break. Summer was upon us and I enjoyed it. It's part of the record. I took a break and came back on August 18, 2020 with a post about Bioasis closing at 50¢.

And I had no issue with DrDR handling communications. That wasn't my function. With respect to Stockhouse and any other public forums, I was an independent commentator, as DrDR and the other CEOs always stated. And that was what my disclaimers always stated. I don't and never did speak publicly for Bioasis. I speak about Bioasis, independently.

DrDR never gave me a directive about anything. It was a suggestion. In any event, I always posted on my own initiative without permission from, or in consultation with Bioasis, as my contract allowed, and just as I still do. If DrDR had a problem with that, she could have cancelled my contract.

There was another conversation with DrDR in September, 2020, the last one we have had. She rambled on for a few minutes but I was left wondering why she called. She mentioned that i had started posting on Stockhouse again. I told her I enjoyed the break. She mentioned, again, as other CEOs has stated, that she considered me to be an indpendent commentator. There was nothing new to me about that. That was always the deal.

She certainly did not inform me that my contract was cancelled, and even had she done so, cancellation in writing was contractually required. I would have informed her of that but it didn't cross my mind because she hadn't said much of anything, let alone anything about our contract.

The fact is, and it's part of the record, can't escape it, I continued to work under that contract for almost another 19 months, until I cancelled the contract, in writing, on December 17, 2021.

jd
<< Previous
Bullboard Posts
Next >>